Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Solitary Liver Lesions of Indeterminate Malignancy – Outcome Following Surgical Resection

DANIEL ANSARI, GUNNAR NORDQVIST, PETER HAMMARLUND, JOSEF DANKIEWICZ, AMMAR MASSOUD and ROLAND ANDERSSON
Anticancer Research September 2012, 32 (9) 3961-3964;
DANIEL ANSARI
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GUNNAR NORDQVIST
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETER HAMMARLUND
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEF DANKIEWICZ
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AMMAR MASSOUD
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROLAND ANDERSSON
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: roland.andersson{at}med.lu.se
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Well-differentiated hepatocellular carcinoma (HCC) may resemble benign liver lesions on initial diagnostic work-up. The validity of surgical resection for preoperatively unclear liver lesions was investigated in this study. Patients and Methods: We conducted a retrospective analysis of 483 patients subjected to liver resection over a 15-year period. Results: Forty-five patients (9%) were considered to have presented with indeterminate solitary lesions. There were 18 cases of HCC (40%) and 27 cases (60%) of benign lesions, most commonly focal nodular hyperplasia (n=18). Patients with HCC had a higher median age as compared to patients with benign pathology (67 vs. 55 years; p=0.002) and the median tumor size was larger (85 vs. 30 mm; p=0.007). Major complications (Clavien grade III or higher) occurred in three cases (7%) and there was no in-hospital mortality. Conclusion: The results favor an aggressive approach, i.e. surgical intervention, to patients presenting with indeterminate solitary liver tumors due to the high likelihood of an underlying HCC.

  • Indeterminate liver tumor
  • hepatocellular carcinoma
  • benign lesion
  • liver resection
  • diagnosis

Hepatocellular carcinoma (HCC) is the fifth most frequent malignancy worldwide. It accounts for approximately 748,000 new cases annually, ranking third amongst cancer-related deaths (1). Established risk factors for HCC are hepatitis B and C virus infections, alcohol-induced liver disease and non-alcoholic fatty liver disease. HCC evolves through a multistep carcinogenic process, involving gene mutations, gene amplifications, chromosomal alterations, and epigenetic modifications (2). Several signaling pathways are consistently reported to be disrupted in HCC. These include for example RAS-RAF-MEK, phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), wingless (Wnt), insulin-like growth factor receptor 1 (IGF1R), hepatocyte growth factor (HGF)/c-MET, vascular endothelial growth factor (VEGF), epithelial growth factor receptor (EGFR), and platelet-derived growth factor (PDGF) (2, 3). Sorafenib, a multikinase inhibitor with proven activity against RAF, VEGF and PDGF, has been shown to prolong survival of patients with advanced HCC (4, 5).

Non-malignant liver tumors are increasingly being detected due to the frequent use of sensitive imaging studies, and they may still sometimes be difficult to differentiate from well-differentiated HCC, despite improvements in preoperative imaging and general diagnostic work-up. The most common benign liver lesion is hemangioma (6). Autopsy reports describe this benign vascular tumor to be present in 3-20% of cases (7). Patients are usually asymptomatic, however, large hemangiomas (>10 cm diameter) can cause abdominal discomfort or other symptoms (8). Focal nodular hyperplasia (FNH) ranks second in terms of incidence among benign lesions, followed by adenomas, cysts and abscesses (7).

In liver surgery, more precise surgical techniques and better control of, e.g. operative hemorrhage, has led to fewer complications such as bile leakage, bleeding and liver failure. Hospital mortality rates have decreased from 10% in the 1980s to <1% in recent studies (9-12). The indication for liver resection has steadily increased to include more high-risk patients (11). Definitions on what is considered as an adequate remnant liver function are, however, being constantly re-evaluated. Although liver resection is generally a safe procedure, the indications for surgery must be appropriate in order to avoid unnecessary interventions. One unanswered question is whether surgical resection should be performed in case of indeterminate liver lesion, i.e. when malignancy cannot be fully ruled-out preoperatively. To our knowledge, this is the first study to estimate the incidence of well-differentiated HCC amongst liver lesions where malignancy cannot be ruled out after initial imaging, blood sampling and biopsy. A comparison of clinical features between malignant and non-malignant cases is also attempted.

Patients and Methods

A retrospective study was conducted after approval from the local Human Ethics Committee. A total of 483 patients undergoing liver resection at the Department of Surgery, Skåne University Hospital, Lund, Sweden, between January 1995 and November 2009, were selected. Consideration for resection included anatomically resectable disease without evidence of extrahepatic spread or gross vascular invasion of e.g. the portal vein or the inferior caval vein. Child-Pugh class C status remained a contraindication for surgery. Resection was performed with Cavitron Ultrasonic Surgical Aspirator (CUSA®; Valleylab, Boulder, Colorado, USA) in the majority of cases or Helix Hydro-Jet® (Erbe Elektromedizin GmbH, Tuebingen, Germany).

For the purposes of this study, an indeterminate liver lesion was defined by preoperative suspicion of HCC with inconclusive imaging and biopsy findings; alpha-fetoprotein (AFP) levels <200 ng/ml (13); and no previous patient history of chronic viral hepatitis (B or C). Thus, 366 resected cases were excluded, being metastases from colorectal cancer (n=278), other malignancies including cholangiocarcinoma and non-colorectal metastatic disease (n=86) and trauma (n=2). Among the remaining 117 cases, the indications for surgery were evaluated and 72 cases were subsequently excluded; 34 cases because of a history of extrahepatic malignancy; 18 because the diagnosis of a benign lesion was made preoperatively and resection was due to symptoms, risk of bleeding or malignant transformation; 9 because the diagnosis of HCC was made preoperatively without doubts; 8 because of AFP levels >200 ng/ml; and 3 because of a history of chronic viral hepatitis (1 with hepatitis B and 2 with hepatitis C). The final study population included 45 patients, who underwent liver resection to rule-out HCC, potentially suspected but not verified. For each patient, information regarding age, sex, preoperative AFP level, tumor size and postoperative complications were recorded. All complications were graded according to a previously validated classification (Clavien-Dindo) (14).

Statistical analysis. Values are expressed as median and range unless otherwise stated. The Mann-Whitney U-test was used for continuous variables. For categorical data, the Chi-Square test was used. Differences of p<0.05 were considered to be statically significant. Analyses were performed using the SPSS computer software (SPSS version 19; IBM Corp., Somers, NY, USA).

Results

During the 15-year study period, 45 patients (9%) with indeterminate lesions were seen at our department. There were 29 women and 16 men, and the median age was 57 (25-84) years.

HCC was detected in 18 (40%) of the patients after final histopathological evaluation of the surgical specimens. The remaining 27 patients (60%) had benign pathology, including FNH (n=18), adenoma (n=6), hemangioma (n=2), and a fibrotic lesion (n=1). Comparisons of preoperative characteristics between malignant and benign cases are shown in Table I. No significant differences were observed in gender or AFP levels. The median age of the HCC group was significantly higher than that seen in the group with benign lesions (67 vs. 55 years; p=0.002). The median tumor size was significantly larger in the HCC group (85 vs. 30 mm; p=0.007).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Preoperative characteristics predicting malignancy.

Postoperative complications occurred in 19 patients (42%); ten in the HCC group and nine in the group with benign tumors (p=0.139). Out of these, three were classified as major, requiring either surgical, radiological or endoscopic intervention (Clavien grade III) or intensive care (Clavien grade IV). Included herein were an intra-abdominal hematoma requiring drainage (one patient), respiratory failure necessitating intubation (one patient) and cardiac failure with hemodynamic instability requiring intensive care (one patient). All major complications occurred in the HCC group. No perioperative death was noted.

Discussion

Despite improvements in imaging techniques, it may occasionally be difficult to preoperatively assess the true nature of a primary, solitary liver tumor. Of all the indeterminate liver lesions, 40% were ultimately found to be HCC in the present analysis. By comparing preoperative results between HCC and benign lesions, we found that age was higher and tumor size increased in the HCC group. The current series was different from previous ones in several aspects. Firstly, only cases with a preoperative suspicion of a potential malignancy but with inconclusive findings on imaging and biopsy were included. Secondly, we did not select patients with underlying chronic hepatitis. Thirdly, only well-differentiated HCC and benign lesions were chosen, as the real difficulty lies in distinguishing benign lesions from well-differentiated HCC. In one study, 58% of patients with liver incidentaloma were ultimately found to harbor malignant tumors (15). Notably, this study included a high percentage of patients with hepatitis B and malignancies other than HCC, for example cholangiocarcinoma. Other studies have reported a malignancy rate amongst liver incidentalomas in the range of 19-37% (16, 17).

The diagnosis of HCC can be performed on the basis of typical findings on four-phase multidetector computed-tomography (CT) or dynamic contrast-enhanced magnetic resonance imaging (MRI) with arterial enhancement and delayed washout (18, 19). In our study, at least two dynamic studies (contrast-enhanced ultrasound, CT or MRI) were used for each patient prior to surgical resection. Although a high level of AFP is not an accurate screening test, an AFP level above 200 ng/ml combined with a focal liver lesion is considered to be diagnostic of HCC (13). Biopsy is suggested when imaging findings are inconclusive, or for lesions in non-cirrhotic livers.

The sensitivity and specificity of imaging modalities in the surgical population are typically lower than those observed in the general population. This could be because of selection bias, where more atypical cases are selected for surgery (20). The design of previous studies that evaluated the diagnostic capacity of imaging methods often exclude atypical cases and include those with an HCC already diagnosed by imaging or by biopsy (21). Therefore, the incidence of “indeterminate” lesions reported here may be higher than previously reported. The role of fine-needle aspiration (FNA) biopsy of liver tumors is debated, mainly because of the increased risk of tumor seeding. The incidence of needle-tract tumor seeding in HCC is estimated to be 2.7% in total, or 0.9% per year (22). Furthermore, FNA biopsy has been associated with a false-negative rate of 30% (21). Efforts have been made to refine the diagnostic criteria using biomarker panels, but so far results are not sufficiently accurate (23-26).

FNH is a rare benign liver tumor that is caused by a congenital arterial malformation leading to hepatocellular hyperplasia. We noted a high proportion of FNH amongst indeterminate lesions. FNH has a hypervascular pattern and may present with atypical features, with some cases bearing close resemblance to HCC (27). Hemangiomas are generally easier to distinguish from other lesions with conventional imaging, but a rapid-filling hemangioma may present without the appearance of a peripheral nodular enhancement in the arterial phase of the CT scan and thus render definite diagnosis difficult (28). FNA biopsy is not recommended given the risk of hemangioma rupture, as well as the low diagnostic yield (29).

The main limitation of the present study is its retrospective nature. Furthermore, several assumptions had to be made a priori. We made the assumption that the cases with a preoperative suspicion of malignancy were found among the patients with a final diagnosis of HCC or a benign lesion. The preferred method would have been to start with the indication for surgery as the primary selection criteria, but this information was not available for all cases. We also made the assumption that patients with a primary tumor in an organ other than the liver were operated on the indication of possible metastases.

In conclusion, we have shown that indeterminate liver lesions are associated with a high risk of being HCC. Increased age and tumor size are associated with a higher likelihood of a malignant finding. As the safety of the liver resection per se is acceptable, we propose an aggressive surgical strategy for patients presenting with liver lesions of uncertain malignancy when initial diagnostic work-up is inconclusive. With the gradual improvement at least of imaging modalities, the percentage of uncertain lesions hopefully will be reduced.

Footnotes

  • Conflict of interest

    The Authors declare no conflict of interest.

  • Received May 7, 2012.
  • Revision received June 29, 2012.
  • Accepted July 2, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Yang JD,
    2. Roberts LR
    : Hepatocellular carcinoma: A global view. Nature reviews. Gastroenterology & hepatology 7: 448-458, 2010.
    OpenUrlPubMed
  2. ↵
    1. Forner A,
    2. Llovet JM,
    3. Bruix J
    : Hepatocellular carcinoma. Lancet 379: 1245-55, 2012.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Tanaka S,
    2. Arii S
    : Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100: 1-8, 2009.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cheng AL,
    2. Kang YK,
    3. Chen Z,
    4. Tsao CJ,
    5. Qin S,
    6. Kim JS,
    7. Luo R,
    8. Feng J,
    9. Ye S,
    10. Yang TS,
    11. Xu J,
    12. Sun Y,
    13. Liang H,
    14. Liu J,
    15. Wang J,
    16. Tak WY,
    17. Pan H,
    18. Burock K,
    19. Zou J,
    20. Voliotis D,
    21. Guan Z
    : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Llovet JM,
    2. Ricci S,
    3. Mazzaferro V,
    4. Hilgard P,
    5. Gane E,
    6. Blanc JF,
    7. de Oliveira AC,
    8. Santoro A,
    9. Raoul JL,
    10. Forner A,
    11. Schwartz M,
    12. Porta C,
    13. Zeuzem S,
    14. Bolondi L,
    15. Greten TF,
    16. Galle PR,
    17. Seitz JF,
    18. Borbath I,
    19. Haussinger D,
    20. Giannaris T,
    21. Shan M,
    22. Moscovici M,
    23. Voliotis D,
    24. Bruix J
    : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Chen MF
    : Hepatic resection for benign tumours of the liver. J Gastroenterol Hepatol 15: 587-592, 2000.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ibrahim S,
    2. Chen CL,
    3. Wang SH,
    4. Lin CC,
    5. Yang CH,
    6. Yong CC,
    7. Jawan B,
    8. Cheng YF
    : Liver resection for benign liver tumors: indications and outcome. Am J Surg 193: 5-9, 2007.
    OpenUrlPubMed
  8. ↵
    1. Clarke DL,
    2. Currie EJ,
    3. Madhavan KK,
    4. Parks RW,
    5. Garden OJ
    : Hepatic resection for benign non-cystic liver lesions. HPB (Oxford) 6: 115-119, 2004.
    OpenUrlPubMed
  9. ↵
    1. Cha CH,
    2. Saif MW,
    3. Yamane BH,
    4. Weber SM
    : Hepatocellular carcinoma: current management. Curr Probl Surg 47: 10-67, 2010.
    OpenUrlPubMed
    1. Nuzzo G,
    2. Giuliante F,
    3. Gauzolino R,
    4. Vellone M,
    5. Ardito F,
    6. Giovannini I
    : Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. Eur J Surg Oncol 33: 1014-1018, 2007.
    OpenUrlPubMed
  10. ↵
    1. Poon RT,
    2. Fan ST,
    3. Lo CM,
    4. Liu CL,
    5. Lam CM,
    6. Yuen WK,
    7. Yeung C,
    8. Wong J
    : Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 240: 698-708; discussion 708-610, 2004.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wu FS,
    2. Zhao WH,
    3. Liang TB,
    4. Ma ZM,
    5. Teng LS,
    6. Wang M,
    7. Zheng SS
    : Survival factors after resection of small hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4: 379-384, 2005.
    OpenUrlPubMed
  12. ↵
    1. Bruix J,
    2. Sherman M
    : Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien PA
    : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Liu CL,
    2. Fan ST,
    3. Lo CM,
    4. Chan SC,
    5. Tso WK,
    6. Ng IO,
    7. Wong J
    : Hepatic resection for incidentaloma. J Gastrointest Surg 8: 785-793, 2004.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Belli G,
    2. D'Agostino A,
    3. Iannelli A,
    4. Marano I
    : Hepatic incidentaloma. Retrospective analysis of 35 cases. Int Surg 81: 144-148, 1996.
    OpenUrlPubMed
  16. ↵
    1. Little JM,
    2. Kenny J,
    3. Hollands MJ
    : Hepatic incidentaloma: A modern problem. World J Surg 14: 448-451, 1990.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bruix J,
    2. Sherman M
    : Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011.
    OpenUrlCrossRefPubMed
  18. ↵
    EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Terkivatan T,
    2. de Wilt JH,
    3. de Man RA,
    4. van Rijn RR,
    5. Zondervan PE,
    6. Tilanus HW,
    7. JN IJ
    : Indications and long-term outcome of treatment for benign hepatic tumors: A critical appraisal. Arch Surg 136: 1033-1038, 2001.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Forner A,
    2. Vilana R,
    3. Ayuso C,
    4. Bianchi L,
    5. Sole M,
    6. Ayuso JR,
    7. Boix L,
    8. Sala M,
    9. Varela M,
    10. Llovet JM,
    11. Bru C,
    12. Bruix J
    : Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47: 97-104, 2008.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Silva MA,
    2. Hegab B,
    3. Hyde C,
    4. Guo B,
    5. Buckels JA,
    6. Mirza DF
    : Needle-track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57: 1592-1596, 2008.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Wang FH,
    2. Yip YC,
    3. Zhang M,
    4. Vong HT,
    5. Chan KI,
    6. Wai KC,
    7. Wen JM
    : Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol 63: 599-603, 2010.
    OpenUrlAbstract/FREE Full Text
    1. Di Tommaso L,
    2. Destro A,
    3. Fabbris V,
    4. Spagnuolo G,
    5. Laura Fracanzani A,
    6. Fargion S,
    7. Maggioni M,
    8. Patriarca C,
    9. Maria Macchi R,
    10. Quagliuolo M,
    11. Borzio M,
    12. Iavarone M,
    13. Sangiovanni A,
    14. Colombo M,
    15. Roncalli M
    : Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 53: 1549-1557, 2011.
    OpenUrlCrossRefPubMed
    1. Llovet JM,
    2. Chen Y,
    3. Wurmbach E,
    4. Roayaie S,
    5. Fiel MI,
    6. Schwartz M,
    7. Thung SN,
    8. Khitrov G,
    9. Zhang W,
    10. Villanueva A,
    11. Battiston C,
    12. Mazzaferro V,
    13. Bruix J,
    14. Waxman S,
    15. Friedman SL
    : A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131: 1758-1767, 2006.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Tremosini S,
    2. Forner A,
    3. Boix L,
    4. Vilana R,
    5. Bianchi L,
    6. Reig M,
    7. Rimola J,
    8. Rodriguez-Lope C,
    9. Ayuso C,
    10. Sole M,
    11. Bruix J
    : Prospective validation of an immunohistochemical panel (glypican 3, heat-shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012 (e-pub ahead of print).
  24. ↵
    1. Choi CS,
    2. Freeny PC
    : Triphasic helical CT of hepatic focal nodular hyperplasia: incidence of atypical findings. AJR Am J Roentgenol 170: 391-395, 1998.
    OpenUrlPubMed
  25. ↵
    1. Jang HJ,
    2. Yu H,
    3. Kim TK
    : Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging 9: 96-103, 2009.
    OpenUrlPubMed
  26. ↵
    1. Bahirwani R,
    2. Reddy KR
    : Review article: The evaluation of solitary liver masses. Aliment Pharmacol Ther 28: 953-965, 2008.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 32, Issue 9
September 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Solitary Liver Lesions of Indeterminate Malignancy – Outcome Following Surgical Resection
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Solitary Liver Lesions of Indeterminate Malignancy – Outcome Following Surgical Resection
DANIEL ANSARI, GUNNAR NORDQVIST, PETER HAMMARLUND, JOSEF DANKIEWICZ, AMMAR MASSOUD, ROLAND ANDERSSON
Anticancer Research Sep 2012, 32 (9) 3961-3964;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Solitary Liver Lesions of Indeterminate Malignancy – Outcome Following Surgical Resection
DANIEL ANSARI, GUNNAR NORDQVIST, PETER HAMMARLUND, JOSEF DANKIEWICZ, AMMAR MASSOUD, ROLAND ANDERSSON
Anticancer Research Sep 2012, 32 (9) 3961-3964;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Incidentally Detected Focal Liver Lesions - A Common Clinical Management Dilemma Revisited
  • Google Scholar

More in this TOC Section

  • A Reminder App for Optimizing Bladder Filling During Radiotherapy for Prostate Cancer: A Pre-study in Healthy Volunteers
  • Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration
  • Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire